# HSEF v5.3 review: Epigenetic Field Cancerization

> Sources: 63 primary reports; claims: 69; verified: 69; unverified: 0. Verification is bounded attribution. Access: 8 partial-body and 55 complete abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-09. No complete-paper audit or blinded calibration claimed.

> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Methylation fields predict risk and can contribute causally, but spontaneous independent initiation of cancer fields remains unestablished.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Γ — Mechanistically plausible, partial system support | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** In a defined uninjured adult epithelial lineage, follow naturally arising promoter epimutant clones with joint genome/methylome profiling, then selectively reverse the candidate methylation while preserving DNA sequence and compare clone fitness and incident cancer with catalytic-dead and matched-expression rescue controls.

**Belief versus evidence:** The registered scope-matched gate SC5 gives Γ. SC2 and SC3 reach Ε in defined engineered or inflammatory settings, while SC1 and SC4 remain Β for causal inference from association. Weakest-link sensitivity is Β. Predictive value and causal contributions are retained without substituting for spontaneous independent field initiation.

**Best-supported rival:** Epigenetic predisposition cooperating with genetic and tissue-state events. Yu provides an engineered endogenous-locus incidence discriminator against a pure-passenger account; Tao and Yang distinguish autonomous initiation from context-dependent sensitization/progression. Prospective Asada and Yamada distinguish prediction from causality, while left-colon nulls delimit generalization.

## COMPETING MECHANISTIC MODELS

**Rank 1: Epigenetic predisposition cooperating with genetic and tissue-state events (Ζ).** Methylation can alter fitness and tumor susceptibility while context and further changes determine malignancy. Native p16 incidence, constitutional MLH1 predisposition, organoid Braf sensitization and Apc-p16 progression are complementary assay classes. The p16 reports share one allele; natural epithelial field initiation and required cooperators are not universally resolved.

**Rank 2: Inflammatory induction with persistent epigenetic memory (Ε).** Inflammatory exposure generates partly durable methylation and alters tissue risk. Colonization-preserving inflammation suppression, withdrawal and exposure comparisons resolve simple bacterial-presence or proliferation explanations. Global immune/repair changes and residual disease effects leave locus-specific cancer mediation incomplete.

**Rank 3: Genetic initiation with epigenetic gatekeeping (Ε).** Selected driver clones can recruit methylation programs or exploit pre-existing epigenetic states. KRAS-ZNF304 and BRAF-MAFG perturbations plus normal-tissue clonal sequencing show defined routes. Tumor-cell results do not make all fields mutation-first; p16 and constitutional MLH1 prevent a categorical genetic-only claim.

**Rank 4: Spontaneous autonomous epigenetic cancer field (Γ).** Normal acquired methylation independently starts and sustains a clonal cancer field. Crypt-level patterns and culture-associated Wnt/stemness changes provide mechanistic plausibility. Prospective marker associations do not isolate clonal causality; native autonomous initiation lacks a positive scope-matched test.

**Rank 5: Age and exposure-associated methylation drift (Β).** Methylation records accumulated age/exposure and tissue state without necessarily driving every lesion. Strong age, inflammatory and organ-specific marker associations plus some normal-field nulls fit this model. Engineered causal p16 and inflammatory DNMT interventions show that a pure passenger explanation is insufficient.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Spontaneous promoter hypermethylation in morphologically normal epithelium independently initiates and sustains pre-neoplastic clonal field expansion and subsequent carcinogenesis.

Register all five index subclaims. SC5 gates spontaneous mutation-independent epithelial initiation; engineered single-locus methylation, inflammatory induction, prediction and abnormal methylation presence are distinct. Age/exposure/genotype controls are antecedent, not responder-defined.

Selection: public-interest rank 48 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

### Evidence and causal interpretation

Normal-tissue methylation fields are real but heterogeneous. Early MGMT spatial work, individual crypt profiling, bilateral breast comparisons and prostate mapping detect changes outside overt tumor. Normal clones are sampled cross-sectionally, and field breadth does not itself establish temporal initiation or independence. Some prostate loci have no measurable field; predominant prostate hypomethylation and LINE-1 findings must be distinguished from promoter hypermethylation. PMID16174854 PMID20395289 PMID18542073 PMID32255732 PMID23555185 PMID18058812

Outlier algorithms refine detection rather than proving a mechanism. Breast outlier studies validate in external samples; OMP occurs in a subgroup of CRC-associated normal mucosa, with expression and microbiome differences. SWEPIC uses normal cecal tissue from 1111 patients and external classifiers, with age and computational cell-composition checks. These are cross-sectional classifiers. Their good discrimination cannot establish prospective incidence or independent epimutation causality. PMID27103033 PMID26823093 PMID36219239 PMID38273663

Prospective gastric cohorts must be retained. Asada preselects three markers, follows annual endoscopy and excludes first-year events likely to be occult baseline cancer. The adjusted highest-versus-lowest quartile miR-124a-3 HR is 2.30 with a wide interval; not every endpoint or marker analysis is significant. Separate miR-34b/c and MOS follow-up support risk prediction, although MOS has substantial protocol noncompletion and mixes later adenomas and cancers. This is temporal prediction, not a methylation-specific incidence intervention. PMID25379950 PMID23942619 PMID35038821

Yamada adds an independent prospective primary-cancer population after eradication with open-type atrophy. Of 1624 followed participants, 27 develop cancer; RIMS1 quartiles differ in incidence with adjusted HR 5.7 and wide uncertainty. Original Results show that marker-to-genome-burden validation uses separate archived samples rather than the full incidence cohort. Further smoking/eradication-duration adjustment is ad hoc. The report strengthens prediction while leaving mediation and generalization outside this selected population open. PMID40240063 PMID37219707

Inflammatory induction has genuine causal contrasts. Niwa suppresses inflammation without removing colonization and blocks methylation induction; withdrawal leaves a partly persistent component. Exposure duration and contrasting inflammation types show that proliferation alone is inadequate. Human repeated biopsies show marker-specific reversibility after eradication. These support a defined induced memory route, and do not show that residual methylation autonomously expands a clone. PMID20124475 PMID27992956 PMID20980348 PMID19821005 PMID35939560

Cancer-prevention interventions show contributions but leave specificity limits. DNMT inhibition reduces tumor incidence in inflammatory gerbil and mouse colon models. Cytokines, immune state and other methylated loci change alongside the measured promoters. MSH2 perturbation links inflammatory DNA damage to early repression, yet the repair protein has broader functions and a linked erratum remains unexamined. These controls prevent interpreting global demethylation as clean proof of a spontaneous methylation-only initiator. PMID23559452 PMID31240997 PMID28522752 PMID30443963

Yu is a critical positive counterweight to an overly categorical genetic-only account. An engineered cis sequence at endogenous p16 produces methylation spreading and reduced expression; insertion controls and reactivation support the mechanism. Mice develop spontaneous tumors without a required engineered oncogene. The cohort is small, the strain background is mixed and tumors include sarcomas and lymphomas as well as lung cancer. This is context-specific epimutation susceptibility, not naturally arising epithelial field independence or proof that subsequent tumors lacked acquired genomic drivers. PMID25061879

Yang extends the same p16 allele, not an independent replication. Targeted demethylation restores fibroblast p16 after the inducing sequence is excised. In intestine, p16 epimutation cooperates with Apc to worsen tumor growth, survival and malignant features, with immune changes and treatment responses. Tissue-level methylation patterns are described as clonal but do not replace joint lineage tracing. The result is a causal cooperative progression model. PMID37143122 PMID25866970

Tao cultured organoids acquire aging-like methylation, Wnt activation and stemness, then become more susceptible to Braf-driven transformation. Gene knockouts and differentiation-factor restoration provide functional contrasts. Early exome data find no additional key drivers at initial transformation, but some selected later outgrowths acquire beta-catenin mutations. Importantly, Braf itself remains present. Culture adaptation, transplantation and genetic gene deletion limit transfer to unperturbed chronological epithelial fields. PMID30753828

Rare constitutional MLH1 epimutations establish a meaningful epigenetic predisposition route. Allele-specific methylation and expression loss occur throughout normal tissues, mosaic parental transmission can yield a nonmosaic affected child, and detailed profiling finds no detected cis variant in many carriers. This argues against requiring an identified coding mutation for every predisposition, while constitutional developmental origin, small families and bounded detection prevent generalizing to common acquired epithelial clones. PMID15064764 PMID26181641 PMID30283143

Competing genetic routes are also directly supported. KRAS-ZNF304 and BRAF-MAFG perturbations identify oncogene-directed silencing in established cancer models. Normal colon, esophagus, skin, bronchial and gastric sequencing demonstrate selected mutant clones before overt cancer; many remain functional, and normal gastric CTNNB1 mutation spectra differ from cancers. Genetically selected clones therefore do not prove inevitable malignancy or exclude epigenetic cooperation. Reused normal-colon control crypts and related pathway studies are grouped. PMID24623306 PMID25219500 PMID26787892 PMID31645730 PMID32697969 PMID30337457 PMID25999502 PMID31996850 PMID40108450

Nulls define legitimate boundaries. Left-colon adjacent tissue lacks most candidate fields despite strong tumor methylation, with negative adjacent hotspot assays. The single-locus estimate differs between abstract and body and is not pooled here. Rectal ACF show no LINE-1 field, and MGMT-to-G-to-A associations fail in a larger series despite positive early findings. These results oppose a universal marker mechanism, rather than denying all epigenetic fields. PMID28540987 PMID25859284 PMID25638164

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

<!-- consensus-consistency-2026-10-09 -->
### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/hsef_v53_popularity_ranks_46_50_2026-10-09/epigenetic-field-cancerization/consensus/browser-pro-broad.txt`
- `deliverables/hsef_v53_popularity_ranks_46_50_2026-10-09/epigenetic-field-cancerization/consensus/browser-pro-targeted.txt`
- `deliverables/hsef_v53_popularity_ranks_46_50_2026-10-09/epigenetic-field-cancerization/consensus/reconciliation.md`
- `deliverables/hsef_v53_popularity_ranks_46_50_2026-10-09/epigenetic-field-cancerization/consensus/usage.json`

Reported usage is preserved in the linked source-specific records; query counts and original-passage comparisons are different measures.

This provenance supplement is not a new independent or blinded adjudication. The original edition of this review carried no adversarial approval; the adversarial review of record is the one recorded in ADVERSARIAL REVIEW AND APPROVAL below. No score or confidence change is made by this reconciliation.
<!-- end-consensus-consistency -->


### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Aberrant DNA methylation is present in morphologically normal epithelium at elevated tumor risk. | organ, age, exposure and normal histology | Β | Normal epithelial methylation fields are reproducible, spatially measurable and often associated with neoplasia. This is robust existence/association evidence, with locus and organ-specific nulls; the Β cancer-association cap does not deny their existence. |
| SC2 Targeted tumor-suppressor promoter hypermethylation raises spontaneous tumor incidence in vivo. | methylated locus, mammalian lineage and genotype | Ε | Endogenous-locus engineered p16 methylation raises spontaneous tumor incidence without a required engineered oncogene. Inserted-sequence controls and reactivation distinguish silencing from simple insertion effects. Small mixed-background cohorts and lack of adult native field demethylation/incidence rescue keep this at context-specific Ε. |
| SC3 Chronic inflammation causally induces durable epithelial DNA methylation. | inflammation/exposure and tissue defined before outcome | Ε | Inflammation suppression despite retained colonization, exposure-duration contrasts, withdrawal and human longitudinal biopsies establish defined inflammatory routes to methylation. Persistence is partly marker-specific; broad immunosuppression, repair changes and limited original-body access prevent a universally resolved induction mechanism. |
| SC4 Methylation in normal mucosa predicts metachronous cancer. | baseline cancer/exposure, organ and follow-up horizon | Β | Several prospective cohorts demonstrate later cancer or neoplasia associations, including independent primary-incidence and metachronous cohorts. The Β association cap applies to causal interpretation, not to the validated predictive signal. Marker alteration has not itself been selectively shown to change human incidence. |
| SC5 Spontaneous endogenous epimutations independently initiate and sustain clonal field expansion. | morphologically normal epithelial clones with baseline genome ascertainment | Γ | Organoid aging-like methylation provides a plausible functional precursor and rare constitutional epimutations establish epigenetic predisposition. No examined positive native epithelial lineage study isolates spontaneously arising methylation as independently initiating and sustaining a cancer field. Engineered p16 tumor sufficiency is narrower than natural clonal-field independence. |

Preregistered aggregation: scope-matched. The registered scope-matched gate SC5 gives Γ. SC2 and SC3 reach Ε in defined engineered or inflammatory settings, while SC1 and SC4 remain Β for causal inference from association. Weakest-link sensitivity is Β. Predictive value and causal contributions are retained without substituting for spontaneous independent field initiation. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[4] Methylation burden increases with exposure and partly persists after withdrawal. Persistence is not proof of autonomous cancer initiation; related gastric platform is grouped.

[9] DNMT inhibition reduces tumorigenesis and persistent inflammatory methylation; derived tumoroids differ in proliferation. Broad drug effects, inflammatory context and shared precursor model prevent isolated spontaneous methylation sufficiency.

[10] Demethylating treatment reduces cancer incidence with lower epithelial methylation. Inflammatory cytokines also change and carcinogen exposure remains; no locus-specific mediation rescue or spontaneous field test.

[11] Preselected mucosal miR-124a-3 methylation predicts authentic later cancers with adjusted HR 2.30 and explicit early-event exclusion. Three-year follow-up, modest events and residual confounding limit causality; not all marker or endpoint analyses are significant.

[13] MSH2 loss prevents early inflammation-associated epigenetic alterations and later hypermethylation. MSH2 also affects repair and tumor biology; linked erratum body remains unexamined, limiting fine mechanistic certainty.

[16] Successful eradication reduces marker methylation with marker-specific kinetics but leaves residual levels above uninfected controls. Nonrandom intervention and cell-composition changes limit mediation; residual risk does not establish autonomous methylated clones.

[17] Probable drivers occur in about 1% of middle-age crypts; normal clonal evolution is genetically measurable. Driver presence is not sufficient for cancer and epigenomes were not jointly measured; mutation-first is not universally proved.

[18] IBD increases mutations and millimetre-scale clonal expansion with tissue-specific positive selection. Control crypts reuse prior normal-colon publication; genetic selection does not exclude cooperative epigenetic effects.

[19] Normal epithelium becomes colonized by positively selected mutant clones, with NOTCH1 more prevalent than in cancers. Cross-sectional clonal genetics does not show every clone is malignant or resolve methylation's additional contribution.

[20] Smoking increases mutational burden and driver prevalence; cessation associates with less-mutated cells. Colony culture and cross-sectional sampling constrain selection inference; no joint methylome lineage test.

[21] Distinct drivers and trisomies occur in normal glands; clone prevalence depends on age and inflammation, with normal/cancer CTNNB1 spectra differing. Normal clones are not equivalent to cancer and methylation is not jointly perturbed; cancer-bearing donors contribute samples.

[22] Positive selection produces abundant cancer-gene mutant clones while tissue remains functional. Four donors and targeted genes constrain coverage; genetic clone existence does not exclude epigenetic cooperation.

[33] LINE-1 field hypomethylation is absent; segment-specific methylation differences are detected. This negative result addresses repeat methylation, not every promoter field; rectal ACF differ from right-colon adenomas.

[38] Locus-directed suppression increases replication and p16 restoration reverses the phenotype. Fibroblast replication is not epithelial malignancy or spontaneous in-vivo incidence; engineered delivery defines scope.

[39] Engineered promoter methylation represses p16 and raises spontaneous tumor incidence without a required engineered oncogene; inserted-sequence controls and expression restoration support mechanism. The initiating allele is engineered DNA; mixed backgrounds, small tumor cohorts, non-epithelial tumor spectrum and absent whole-genome lineage/rescue constrain natural-field transfer.

[40] KRAS-linked ZNF304 recruitment mediates DNMT1-associated CIMP silencing. Cancer-cell dependency is not universal mutation-first initiation; related RNAi platform is grouped.

[41] BRAF-MAFG corepressor pathway directs methylation-linked silencing in two cancer settings. Shares pathway/platform with earlier CRC report; no proof that all natural methylation fields originate genetically.

[42] Spontaneous culture-associated methylation creates Wnt/stemness changes and sharply accelerates Braf-dependent transformation. Culture aging is not chronological native epithelium; Braf is required in the tested transformation comparison and some selected outgrowths acquire Wnt mutations.

[43] MAFG depletion resolves an oncogene-directed MLH1/CIMP repression pathway. Related study line and established tumor cells limit initiation transfer; does not erase epigenetic-first sensitization.

[49] p16 epimutation cooperates with Apc, changes immune milieu and tumor progression; targeted demethylation restores p16 in fibroblasts. Shared cis-element lineage with Yu; tumors arise in Apc-mutant context and broad drug/immune effects prevent autonomous initiation inference.

[53] Baseline miR-34b/c predicts later cancer after covariate adjustment in 129 patients. Seventeen events and observational tissue markers do not establish independent methylation-driven initiation.

[54] Baseline MOS predicts later metachronous neoplasms with adjusted HR 4.76. Only 124 of 294 completed the protocol; outcome mixes adenomas and seven cancers and threshold requires external validation.

[59] Most candidate methylation fields are absent despite strong tumor signals; adjacent hotspots are negative. Candidate panel and modest cohort cannot exclude every epimutation; abstract/body single-locus estimates differ and are not pooled.

[60] Suppressing inflammation leaves bacterial colonization intact but blocks methylation induction; withdrawal leaves a residual component. Broad immunosuppression and exposure-defined tissue do not isolate autonomous methylation-mediated cancer initiation.

[62] Strong proliferation alone fails to induce the same methylation; inflammatory type matters. Related gastric platform and different exposures limit independent replication; outcome is methylation rather than cancer incidence.

[63] 1624 followed participants with 27 incident cancers validate RIMS1 risk gradients with adjusted HR 5.7. Wide interval and atrophy-selected population constrain transfer; marker burden validation uses separate archived samples, and methylation is not experimentally altered.

Tally: 26 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

### Cap audit, precedence and Β/Γ/Δ boundary

Native in-vivo incidence and inflammatory interventions cross thresholds for defined SC2/SC3 scopes. They cannot lift SC5 without a positive test of spontaneous independent native clonal initiation. The Γ simplified-system cap binds the organoid-to-native-field transfer, and the Β association cap binds causal transfer from prospective marker prediction.

Gamma hard-rule audit: Spatial normal-tissue methylation and later disease association do not identify an independently expanding causal clone. Organoid transformation, engineered cis-sequence methylation and constitutional epimutations require separate scope labels; no absence-of-detected-mutation claim is whole-genome proof.

SC1 cap: “**Association-only cancer claims cap at Β.**” Normal epithelial methylation fields are reproducible, spatially measurable and often associated with neoplasia. This is robust existence/association evidence, with locus and organ-specific nulls; the Β cancer-association cap does not deny their existence.

SC4 cap: “**Association-only cancer claims cap at Β.**” Several prospective cohorts demonstrate later cancer or neoplasia associations, including independent primary-incidence and metachronous cohorts. The Β association cap applies to causal interpretation, not to the validated predictive signal. Marker alteration has not itself been selectively shown to change human incidence.

SC5 cap: “Mechanistically plausible cell culture or transplantation-linked models without endogenous in vivo dependency cap at Γ.” Organoid aging-like methylation provides a plausible functional precursor and rare constitutional epimutations establish epigenetic predisposition. No examined positive native epithelial lineage study isolates spontaneously arising methylation as independently initiating and sustaining a cancer field. Engineered p16 tumor sufficiency is narrower than natural clonal-field independence.

SC1 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Normal epithelial methylation fields are reproducible, spatially measurable and often associated with neoplasia. This is robust existence/association evidence, with locus and organ-specific nulls; the Β cancer-association cap does not deny their existence.

SC2 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: yes. Endogenous-locus engineered p16 methylation raises spontaneous tumor incidence without a required engineered oncogene. Inserted-sequence controls and reactivation distinguish silencing from simple insertion effects. Small mixed-background cohorts and lack of adult native field demethylation/incidence rescue keep this at context-specific Ε.

SC3 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: yes. Inflammation suppression despite retained colonization, exposure-duration contrasts, withdrawal and human longitudinal biopsies establish defined inflammatory routes to methylation. Persistence is partly marker-specific; broad immunosuppression, repair changes and limited original-body access prevent a universally resolved induction mechanism.

SC4 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Several prospective cohorts demonstrate later cancer or neoplasia associations, including independent primary-incidence and metachronous cohorts. The Β association cap applies to causal interpretation, not to the validated predictive signal. Marker alteration has not itself been selectively shown to change human incidence.

SC5 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Organoid aging-like methylation provides a plausible functional precursor and rare constitutional epimutations establish epigenetic predisposition. No examined positive native epithelial lineage study isolates spontaneously arising methylation as independently initiating and sustaining a cancer field. Engineered p16 tumor sufficiency is narrower than natural clonal-field independence.

### Upward threshold ladder

SC1 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. Joint normal-cell genotype, methylome and lineage follow-up with causal fitness perturbation rather than association alone.

SC2 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: yes. 

SC2 Ε: “Requires context-specific causal validity with explicit limits. Cancer stem cells often belong here when a stem-like hierarchy exists in some tumor contexts but fails as a universal model.” Satisfied: yes. 

SC2 Ζ: “Requires:
- Independent causal confirmation across models
- Reduced viability of major alternatives
- Relevance beyond one assay class” Satisfied: no. Adult native epithelial methylation induction with sequence-preserving catalytic controls and locus-specific reversal of spontaneous tumor incidence in independently replicated tissues.

SC3 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: yes. 

SC3 Ε: “Requires context-specific causal validity with explicit limits. Cancer stem cells often belong here when a stem-like hierarchy exists in some tumor contexts but fails as a universal model.” Satisfied: yes. 

SC3 Ζ: “Requires:
- Independent causal confirmation across models
- Reduced viability of major alternatives
- Relevance beyond one assay class” Satisfied: no. Cell-resolved inflammatory withdrawal with selective epithelial mediator perturbation and matched restoration, preserving proliferation, immune composition and viability.

SC4 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. A calibrated externally validated incidence model can strengthen prediction; a causal claim additionally needs selective marker/pathway alteration that changes incidence with confounding controlled.

SC5 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. Prospective native lineage tracing of spontaneous epimutant normal epithelial clones with whole-genome profiling and selective methylation reversal that removes their fitness/cancer advantage before acquired drivers.

Upper ladder: Upper rungs are live without a clinical RCT: native lineage and locus-specific interventions, natural constitutional epimutations, withdrawal and independent incidence cohorts can exclude different errors. Together they support a cooperative causal model, while the nominal independent field still lacks sequence-preserving native initiation/rescue.

Independence: Model-level cooperation converges across genetic incidence, constitutional natural variation and experimentally separated gene function. Prospective cohorts exclude reverse timing of the measured marker but do not exclude unmeasured predisposition. Reused controls, p16 lineage and related gastric platforms are grouped.

Native locus-specific tumor susceptibility [39, 49]: Incidence and conditional Apc progression differ from marker correlation, but share one cis allele and count as one genetic platform.

Human constitutional epigenetic predisposition [44, 8, 45]: Allele-specific expression, inheritance and molecular profiling exclude a simple tumor-contamination account, within rare constitutional rather than acquired field scope.

Independent organoid gene-function contrast [42, 38]: Braf sensitization and matched p16 expression rescue exclude purely descriptive methylation; artificial culture/targeting remain shared class limitations.

### Falsification and pitfalls

Predicted generality fails in a prespecified tissue. PMID28540987 finds most tested fields absent in left-colon adjacent mucosa; PMID25859284 finds no LINE-1 field. Marker-panel nulls restrict scope rather than erase all methylation fields. Additional downgrade: False.

Proposed autonomous feature requires cooperating context in a functional test. PMID30753828 culture-associated methylation accelerates Braf-dependent transformation; PMID37143122 tests Apc cooperation. Yu supports narrower engineered susceptibility. Additional downgrade: False.

Prediction substituted for causality. Prospective HRs show temporal risk association, not that the methylated marker independently creates cancer.

Engineering substituted for spontaneous initiation. Yu uses an altered cis DNA sequence; spontaneous subsequent tumors do not make the initiating epimutation naturally acquired.

Genetic-only rival overclaimed. Constitutional MLH1 and targeted p16 support epigenetic predisposition; normal driver clones can remain functional and nonmalignant.

Provider retrieval absence treated as missing literature. Consensus missed prospective cohorts and attached Niwa primary results to a narrative review identifier; corrected canonical records govern.

### Adversarial steelman: above, then below

Δ steelman: Yu is a native locus and raises spontaneous tumor incidence, while constitutional MLH1 cases have no detected cis mutation. Those results establish defined epigenetic susceptibility, but neither demonstrates naturally acquired epithelial field initiation and sustained clonal growth independently of additional changes. The preregistered SC5 positive crossing is missing.

Β steelman: normal fields are largely biomarkers. Tao gene-function and culture-aging contrasts, locus-specific p16 controls and epimutation predisposition provide real mechanistic plausibility beyond spatial association, retaining Γ for the nominal gate.

Γ retains causal epigenetic contributions while refusing scope transfer to autonomous naturally acquired epithelial field initiation.

### Final score, causal direction and M/S/D

The registered scope-matched gate SC5 gives Γ. SC2 and SC3 reach Ε in defined engineered or inflammatory settings, while SC1 and SC4 remain Β for causal inference from association. Weakest-link sensitivity is Β. Predictive value and causal contributions are retained without substituting for spontaneous independent field initiation.

Cancer is not established as the sole producer of the field (step 1), and functional methylation interventions establish causal contributions (step 2). Naturally independent rate-limiting initiation is not established (step 3), nor is universal methylation necessity (step 4). Defined methylation loss of suppressor function amplifies susceptibility and maintains progression with cooperating context, matching step 5. This does not make every methylated marker functional.

Momentum: Mechanistic only. Recent Yang mechanistic and Yamada prospective reports test cooperation and risk; no verified ongoing native spontaneous-field independence experiment is claimed.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

In a defined uninjured adult epithelial lineage, follow naturally arising promoter epimutant clones with joint genome/methylome profiling, then selectively reverse the candidate methylation while preserving DNA sequence and compare clone fitness and incident cancer with catalytic-dead and matched-expression rescue controls.

Readout: Native clone survival/expansion, suppressor expression, new driver acquisition and spontaneous cancer incidence. Controls: Age/organ/exposure matching, cell-state and inflammation controls, off-target methylome/genome audit, selective reversal and matched restoration. Supporting: Methylation precedes and independently confers clonal expansion and cancer propensity; selective reversal removes the advantage and matched restoration returns it without cooperating genomic changes. Falsifying: Clone fitness follows driver mutations or inflammatory state, selective reversal leaves progression intact, or only engineered/cooperating contexts produce cancer.

## RESEARCH TIMELINE

| Year | Milestone | Primary source | Interpretation |
|---|---|---|---|
| 2004 | Constitutional MLH1 epimutation | [PMID15064764](https://pubmed.ncbi.nlm.nih.gov/15064764/) | Rare epigenetic predisposition, distinct from acquired epithelial fields |
| 2005 | Spatial MGMT field | [PMID16174854](https://pubmed.ncbi.nlm.nih.gov/16174854/) | Association beyond overt tumor |
| 2008 | Normal-colon CGI profiling | [PMID18542073](https://pubmed.ncbi.nlm.nih.gov/18542073/) | Age and disease-related marker fields |
| 2010 | Inflammation-specific methylation induction | [PMID20124475](https://pubmed.ncbi.nlm.nih.gov/20124475/) | Suppression and withdrawal constrain mechanism |
| 2013 | Demethylation reduces inflammatory tumor incidence | [PMID23559452](https://pubmed.ncbi.nlm.nih.gov/23559452/) | Causal contribution with global drug effects |
| 2014 | Targeted p16 incidence model | [PMID25061879](https://pubmed.ncbi.nlm.nih.gov/25061879/) | Engineered susceptibility without required engineered oncogene |
| 2015 | Prospective metachronous gastric prediction | [PMID25379950](https://pubmed.ncbi.nlm.nih.gov/25379950/) | Temporal risk association |
| 2017 | Left-colon field null | [PMID28540987](https://pubmed.ncbi.nlm.nih.gov/28540987/) | Organ/segment/marker boundary |
| 2019 | Aging-like methylation and Braf sensitization | [PMID30753828](https://pubmed.ncbi.nlm.nih.gov/30753828/) | Cooperative organoid mechanism |
| 2019 | Normal-colon driver landscape | [PMID31645730](https://pubmed.ncbi.nlm.nih.gov/31645730/) | Genetic clonal alternative |
| 2022 | OMP normal-mucosal subgroup | [PMID36219239](https://pubmed.ncbi.nlm.nih.gov/36219239/) | Cross-sectional biomarker candidate |
| 2023 | p16/Apc progression | [PMID37143122](https://pubmed.ncbi.nlm.nih.gov/37143122/) | Shared allele with new cooperative context |
| 2024 | SWEPIC classifier validation | [PMID38273663](https://pubmed.ncbi.nlm.nih.gov/38273663/) | Classification, not subsequent incidence |
| 2025 | Independent primary gastric incidence cohort | [PMID40240063](https://pubmed.ncbi.nlm.nih.gov/40240063/) | Prospective prediction strengthened |
| 2025 | Normal gastric clonal genetics | [PMID40108450](https://pubmed.ncbi.nlm.nih.gov/40108450/) | Distinct normal/cancer selection and inflammatory boundaries |

## KNOWLEDGE GAPS

Joint longitudinal genome/epigenome lineage data are needed to identify whether spontaneous methylation precedes and causes native clonal fitness.

Separate marker burden from the specific functional methylated drivers that mediate incidence.

Test locus-specific adult epithelial reversal rather than relying on global demethylating drug effects.

Externally validate prospective gastric thresholds and colorectal OMP/SWEPIC incidence prediction without conflating case-control AUC with future risk.

Resolve organ and segment boundaries with matched cell composition, age and exposure controls.

Distinguish constitutional epimutations from acquired normal epithelial fields and quantify undetected genetic contributions.

Examine the linked MSH2 erratum body and complete supplements before publication-grade mechanism claims.

Reconcile the single-locus abstract/body discrepancy in the left-colon null report before quoting that estimate.

## METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Provider statements about Methods/Results and any returned passages were compared with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful original-passage comparisons are distinguished from provider summaries and assertions of access. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

## REVIEWER NOTES

63 primary reports have complete abstract/status examinations, eight with selected original-body receipts. A narrative Niwa review was removed despite its inadequate publication-type label. Conference abstracts and duplicate preprints were excluded. Consensus contributed discovery and correction prompts, with one abstract-summary/original-body aspect comparison and zero provider-returned verbatim original body passages. This is a bounded critical review, not exhaustive or independently blinded.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14. This is the revised (9 October 2026) edition; the original edition was not adversarially reviewed, so this is the first adversarial review of this case.

**Scope of checks:** All 63 reference PMIDs re-fetched with the PubMed MCP tool get_article_metadata (title, first author, journal, year, DOI): 63/63 resolve to the stated record; no retraction or expression of concern. 12 load-bearing claims spot-checked against PubMed abstracts: refs 11, 21, 42, 44 (Yu, PMID 25061879), 49 (Yang, PMID 37143122), 53, 60 (Niwa, PMID 20124475), 63 (Yamada, PMID 40240063), plus the MLH1 constitutional-epimutation and normal-tissue clonal-sequencing claims. Scoring logic checked against the archived HSEF v5.3 framework, with particular attention to the declared scope-matched aggregation rule. The four Consensus artifacts named in the provenance block were confirmed to exist on disk. Known upstream defects checked: collective-author dropping (none present), empty DOI fields (none), erratum "PMIDnot supplied" strings (none), rendering defects (one found, corrected).

**Findings and corrections**

| ID | Severity | Location | Original -> corrected | Evidence |
|---|---|---|---|---|
| EF-1 | Major | Consensus provenance reconciliation block (also consensus-addendum.md) | "The earlier adversarial approval refers to its original edition; ..." -> "...The original edition of this review carried no adversarial approval; the adversarial review of record is the one recorded in ADVERSARIAL REVIEW AND APPROVAL below." | The original edition, hsef_v53_popularity_ranks_46_50_2026-10-09/epigenetic-field-cancerization/epigenetic-field-cancerization.review.md, contains no adversarial banner and no ADVERSARIAL REVIEW AND APPROVAL section, and this slug is absent from the 2026-10-06 approved set. The 9 October revision asserted an approval that does not exist. This is a regression introduced by the revision, not an inherited error. |
| EF-2 | Minor | Β/Γ/Δ boundary paragraph | "step1 ... step2 ... step3 ... step4 ... step5" -> "step 1 ... step 5" | Known missing-space rendering defect. |
| EF-3 | Major | scorecard final_score.confidence_rationale | "...8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence..." -> rationale resting on density and reproducibility: the two engineered p16 reports share one allele and are not independent lines, the organoid result is culture- and transplantation-dependent, field evidence is largely cross-sectional, prospective cohorts carry wide intervals, and organ/segment nulls and one abstract-versus-body discrepancy remain unresolved | Lead policy: reading access is not evidence density or reproducibility and cannot set a band. Re-derived under the two-step test, the band stays **Moderate** - the review documents substantive reproducibility and evidence-quality reservations, well short of the High text's "extensive independent replication across labs, models, and assay modalities". No level or confidence change. |

**Rejected findings (checked, no change)**

- Scope-matched aggregation: applied correctly. SC5 is the only subclaim whose scope matches the registered claim (spontaneous endogenous epimutations independently initiating and sustaining a clonal field) and it sets the Γ headline; the Ε subclaims SC2 and SC3 are scope-restricted to an engineered locus and to defined inflammatory settings and are reported separately, exactly as the rule requires. The published sensitivities (weakest-link Β, primary-subclaim Γ, scope-matched Γ) are arithmetically consistent with the matrix.
- "Best-supported rival": correctly rendered here. models_evaluated[0] is M2, is_nominal false, rank_in_tournament 1; the review's own nominal model (M1, "Spontaneous autonomous epigenetic cancer field") is correctly placed at rank 4 and is not presented as the rival.
- Yu (PMID 25061879): "Engineered p16(Ink4a) promoter hypermethylation ... increased the incidence of spontaneous cancers" matches the abstract, as does the absence of a required engineered oncogene and the accelerated onset in the germline-mutation/somatic-epimutation compound. The review's caution that the two p16 reports share one allele is correct and is applied to the independence basis.
- Yamada (PMID 40240063): 1624 followed participants, 27 incident cancers, age- and sex-adjusted HR 5.7 with a wide interval - all match the abstract, and the review does not promote the predictive result to causal mediation.
- Asada (PMID 25379950): three preselected markers, annual endoscopy, exclusion of first-year events as likely occult baseline cancer - all match the abstract; the quoted adjusted quartile HR is the multivariate figure from the body, and the univariate 2.17 (1.07-4.41) is consistent with it.
- Niwa (PMID 20124475): inflammation suppression with cyclosporin A did not affect colonization but blocked methylation induction, and post-eradication levels fell yet stayed above uninfected controls - the review's "partly persistent component" wording matches.
- Momentum "Mechanistic only": the named artifacts are completed mechanistic and prospective reports, and the review explicitly declines to claim an ongoing native spontaneous-field independence experiment. Correct under the lead's momentum policy.
- REVIEWER NOTES and the Consensus block are mutually consistent: the notes record discovery and correction prompts with one abstract-summary/original-body aspect comparison and zero provider-returned verbatim body passages. No contradiction of the kind seen elsewhere in this batch.
- Reference 42 prints "BrafV600E-Induced Tumorigenesis" and reference 63 prints "eradication of H. pylori" where the PubMed title field drops the superscript and the italicised species name: rejected per the stated convention.
- Print/e-pub year differences of +/-1 at refs 2, 11, 15, 16, 29, 53 and 62: acceptable under the stated convention.
- Validator warning `v5.claim_form` ("entry_form is 'phenomenon'"): rejected per the standing convention. The restatement grades a causal claim - spontaneous hypermethylation independently initiating and sustaining field expansion **and** subsequent carcinogenesis - not a bare topic.

**Residual limitations**

- 55 of 63 sources were verified at abstract/status depth. Per lead policy this bounds what was checked and is not a determinant of the confidence band.
- The linked MSH2 erratum body and the left-colon abstract-versus-body single-locus discrepancy remain unexamined; the review already flags both in KNOWLEDGE GAPS and does not quote the disputed estimate.
- scorecard provenance_header.generated_by is unchanged; authorship is recorded here as Sol 6.1 per the mandate.
- Package-level files were not edited; propagation strings are listed in the agent report.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Krishnan V, Lim DXE, Hoang PM et al. DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia. Gut. 2020. [PMID 31937549](https://pubmed.ncbi.nlm.nih.gov/31937549/). DOI: 10.1136/gutjnl-2019-319002. Access: abstract_metadata. Study: PMID31937549.

2. Takeshima H, Niwa T, Takahashi T et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer letters. 2015. [PMID 25462860](https://pubmed.ncbi.nlm.nih.gov/25462860/). DOI: 10.1016/j.canlet.2014.11.038. Access: abstract_metadata. Study: PMID25462860.

3. Takeuchi C, Yamashita S, Liu YY et al. Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation. Gut. 2024. [PMID 37751933](https://pubmed.ncbi.nlm.nih.gov/37751933/). DOI: 10.1136/gutjnl-2023-329492. Access: abstract_metadata. Study: PMID37751933.

4. Takeshima H, Niwa T, Toyoda T et al. Degree of methylation burden is determined by the exposure period to carcinogenic factors. Cancer science. 2017. [PMID 27992956](https://pubmed.ncbi.nlm.nih.gov/27992956/). DOI: 10.1111/cas.13136. Access: abstract_metadata. Study: Ushijima-gerbil-inflammation-platform.

5. Kamiyama H, Suzuki K, Maeda T et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene. 2012. [PMID 22310288](https://pubmed.ncbi.nlm.nih.gov/22310288/). DOI: 10.1038/onc.2011.652. Access: abstract_metadata. Study: PMID22310288.

6. Lee OJ, Schneider-Stock R, McChesney PA et al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia (New York, N.Y.). 2005. [PMID 16229808](https://pubmed.ncbi.nlm.nih.gov/16229808/). DOI: 10.1593/neo.05328. Access: abstract_metadata. Study: PMID16229808.

7. Mäki-Nevala S, Ukwattage S, Olkinuora A et al. Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer. International journal of cancer. 2021. [PMID 33521965](https://pubmed.ncbi.nlm.nih.gov/33521965/). DOI: 10.1002/ijc.33492. Access: abstract_metadata. Study: PMID33521965.

8. Sloane MA, Nunez AC, Packham D et al. Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal Cancer. JAMA oncology. 2015. [PMID 26181641](https://pubmed.ncbi.nlm.nih.gov/26181641/). DOI: 10.1001/jamaoncol.2015.1484. Access: abstract_metadata. Study: PMID26181641.

9. Maiuri AR, Savant SS, Podicheti R et al. DNA methyltransferase inhibition reduces inflammation-induced colon tumorigenesis. Epigenetics. 2019. [PMID 31240997](https://pubmed.ncbi.nlm.nih.gov/31240997/). DOI: 10.1080/15592294.2019.1634986. Access: abstract_metadata. Study: O-Hagan-inflammatory-colon-platform.

10. Niwa T, Toyoda T, Tsukamoto T et al. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer prevention research (Philadelphia, Pa.). 2013. [PMID 23559452](https://pubmed.ncbi.nlm.nih.gov/23559452/). DOI: 10.1158/1940-6207.CAPR-12-0369. Access: abstract_metadata. Study: PMID23559452.

11. Asada K, Nakajima T, Shimazu T et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015. [PMID 25379950](https://pubmed.ncbi.nlm.nih.gov/25379950/). DOI: 10.1136/gutjnl-2014-307094. Access: full_text_partial. Study: PMID25379950.

12. Sasaki A, Takeshima H, Yamashita S et al. Severe induction of aberrant DNA methylation by nodular gastritis in adults. Journal of gastroenterology. 2024. [PMID 38499886](https://pubmed.ncbi.nlm.nih.gov/38499886/). DOI: 10.1007/s00535-024-02094-y. Access: abstract_metadata. Study: PMID38499886.

13. Maiuri AR, Peng M, Podicheti R et al. Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis. Cancer research. 2017. [PMID 28522752](https://pubmed.ncbi.nlm.nih.gov/28522752/). DOI: 10.1158/0008-5472.CAN-17-0056. Access: abstract_metadata. Study: O-Hagan-inflammatory-colon-platform.

14. Yoshida T, Kato J, Maekita T et al. Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2013. [PMID 23292007](https://pubmed.ncbi.nlm.nih.gov/23292007/). DOI: 10.1007/s10120-012-0230-x. Access: abstract_metadata. Study: PMID23292007.

15. Hattori N, Niwa T, Ishida T et al. Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model. Cancer science. 2019. [PMID 30443963](https://pubmed.ncbi.nlm.nih.gov/30443963/). DOI: 10.1111/cas.13880. Access: abstract_metadata. Study: PMID30443963.

16. Nakajima T, Enomoto S, Yamashita S et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. Journal of gastroenterology. 2010. [PMID 19821005](https://pubmed.ncbi.nlm.nih.gov/19821005/). DOI: 10.1007/s00535-009-0142-7. Access: abstract_metadata. Study: PMID19821005.

17. Lee-Six H, Olafsson S, Ellis P et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019. [PMID 31645730](https://pubmed.ncbi.nlm.nih.gov/31645730/). DOI: 10.1038/s41586-019-1672-7. Access: abstract_metadata. Study: normal-colon-WGS-platform.

18. Olafsson S, McIntyre RE, Coorens T et al. Somatic Evolution in Non-neoplastic IBD-Affected Colon. Cell. 2020. [PMID 32697969](https://pubmed.ncbi.nlm.nih.gov/32697969/). DOI: 10.1016/j.cell.2020.06.036. Access: abstract_metadata. Study: IBD-WGS-with-reused-control-crypts.

19. Martincorena I, Fowler JC, Wabik A et al. Somatic mutant clones colonize the human esophagus with age. Science (New York, N.Y.). 2018. [PMID 30337457](https://pubmed.ncbi.nlm.nih.gov/30337457/). DOI: 10.1126/science.aau3879. Access: abstract_metadata. Study: PMID30337457.

20. Yoshida K, Gowers KHC, Lee-Six H et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020. [PMID 31996850](https://pubmed.ncbi.nlm.nih.gov/31996850/). DOI: 10.1038/s41586-020-1961-1. Access: abstract_metadata. Study: PMID31996850.

21. Coorens THH, Collord G, Jung H et al. The somatic mutation landscape of normal gastric epithelium. Nature. 2025. [PMID 40108450](https://pubmed.ncbi.nlm.nih.gov/40108450/). DOI: 10.1038/s41586-025-08708-6. Access: full_text_partial. Study: PMID40108450.

22. Martincorena I, Roshan A, Gerstung M et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (New York, N.Y.). 2015. [PMID 25999502](https://pubmed.ncbi.nlm.nih.gov/25999502/). DOI: 10.1126/science.aaa6806. Access: abstract_metadata. Study: PMID25999502.

23. Teschendorff AE, Jones A, Widschwendter M. Stochastic epigenetic outliers can define field defects in cancer. BMC bioinformatics. 2016. [PMID 27103033](https://pubmed.ncbi.nlm.nih.gov/27103033/). DOI: 10.1186/s12859-016-1056-z. Access: abstract_metadata. Study: PMID27103033.

24. Yang B, Bhusari S, Kueck J et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia (New York, N.Y.). 2013. [PMID 23555185](https://pubmed.ncbi.nlm.nih.gov/23555185/). DOI: 10.1593/neo.13280. Access: abstract_metadata. Study: PMID23555185.

25. Belshaw NJ, Elliott GO, Foxall RJ et al. Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. British journal of cancer. 2008. [PMID 18542073](https://pubmed.ncbi.nlm.nih.gov/18542073/). DOI: 10.1038/sj.bjc.6604432. Access: abstract_metadata. Study: PMID18542073.

26. Mehrotra J, Varde S, Wang H et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. The Prostate. 2008. [PMID 18058812](https://pubmed.ncbi.nlm.nih.gov/18058812/). DOI: 10.1002/pros.20675. Access: abstract_metadata. Study: PMID18058812.

27. Guo M, House MG, Hooker C et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. [PMID 15297416](https://pubmed.ncbi.nlm.nih.gov/15297416/). DOI: 10.1158/1078-0432.CCR-03-0763. Access: abstract_metadata. Study: PMID15297416.

28. Alonso S, Dai Y, Yamashita K et al. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget. 2015. [PMID 25638164](https://pubmed.ncbi.nlm.nih.gov/25638164/). DOI: 10.18632/oncotarget.2852. Access: abstract_metadata. Study: PMID25638164.

29. Yoshida S, Yamashita S, Niwa T et al. Epigenetic inactivation of FAT4 contributes to gastric field cancerization. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017. [PMID 26792292](https://pubmed.ncbi.nlm.nih.gov/26792292/). DOI: 10.1007/s10120-016-0593-5. Access: abstract_metadata. Study: PMID26792292.

30. Kisiel JB, Garrity-Park MM, Taylor WR et al. Methylated eyes absent 4 (EYA4) gene promotor in non-neoplastic mucosa of ulcerative colitis patients with colorectal cancer: evidence for a field effect. Inflammatory bowel diseases. 2013. [PMID 23867875](https://pubmed.ncbi.nlm.nih.gov/23867875/). DOI: 10.1097/MIB.0b013e31829b3f4d. Access: abstract_metadata. Study: PMID23867875.

31. Svrcek M, Buhard O, Colas C et al. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut. 2010. [PMID 20947886](https://pubmed.ncbi.nlm.nih.gov/20947886/). DOI: 10.1136/gut.2009.194787. Access: abstract_metadata. Study: PMID20947886.

32. Muse ME, Titus AJ, Salas LA et al. Enrichment of CpG island shore region hypermethylation in epigenetic breast field cancerization. Epigenetics. 2020. [PMID 32255732](https://pubmed.ncbi.nlm.nih.gov/32255732/). DOI: 10.1080/15592294.2020.1747748. Access: abstract_metadata. Study: PMID32255732.

33. Quintanilla I, Lopez-Cerón M, Jimeno M et al. LINE-1 hypomethylation is neither present in rectal aberrant crypt foci nor associated with field defect in sporadic colorectal neoplasia. Clinical epigenetics. 2014. [PMID 25859284](https://pubmed.ncbi.nlm.nih.gov/25859284/). DOI: 10.1186/1868-7083-6-24. Access: abstract_metadata. Study: PMID25859284.

34. Suzuki H, Yamamoto E, Nojima M et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010. [PMID 20924086](https://pubmed.ncbi.nlm.nih.gov/20924086/). DOI: 10.1093/carcin/bgq203. Access: abstract_metadata. Study: PMID20924086.

35. Maeda M, Yamashita S, Shimazu T et al. Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018. [PMID 29427040](https://pubmed.ncbi.nlm.nih.gov/29427040/). DOI: 10.1007/s10120-018-0803-4. Access: abstract_metadata. Study: PMID29427040.

36. Yamashita S, Kishino T, Takahashi T et al. Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues. Proceedings of the National Academy of Sciences of the United States of America. 2018. [PMID 29358395](https://pubmed.ncbi.nlm.nih.gov/29358395/). DOI: 10.1073/pnas.1717340115. Access: abstract_metadata. Study: PMID29358395.

37. Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Molecular cell. 2009. [PMID 19450526](https://pubmed.ncbi.nlm.nih.gov/19450526/). DOI: 10.1016/j.molcel.2009.04.001. Access: abstract_metadata. Study: PMID19450526.

38. Bernstein DL, Le Lay JE, Ruano EG et al. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. The Journal of clinical investigation. 2015. [PMID 25866970](https://pubmed.ncbi.nlm.nih.gov/25866970/). DOI: 10.1172/JCI77321. Access: abstract_metadata. Study: PMID25866970.

39. Yu DH, Waterland RA, Zhang P et al. Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice. The Journal of clinical investigation. 2014. [PMID 25061879](https://pubmed.ncbi.nlm.nih.gov/25061879/). DOI: 10.1172/JCI76507. Access: full_text_partial. Study: Shen-p16-cis-lineage.

40. Serra RW, Fang M, Park SM et al. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. eLife. 2014. [PMID 24623306](https://pubmed.ncbi.nlm.nih.gov/24623306/). DOI: 10.7554/eLife.02313. Access: abstract_metadata. Study: PMID24623306.

41. Fang M, Hutchinson L, Deng A et al. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proceedings of the National Academy of Sciences of the United States of America. 2016. [PMID 26787892](https://pubmed.ncbi.nlm.nih.gov/26787892/). DOI: 10.1073/pnas.1525619113. Access: abstract_metadata. Study: Green-MAFG-pathway.

42. Tao Y, Kang B, Petkovich DA et al. Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis. Cancer cell. 2019. [PMID 30753828](https://pubmed.ncbi.nlm.nih.gov/30753828/). DOI: 10.1016/j.ccell.2019.01.005. Access: full_text_partial. Study: PMID30753828.

43. Fang M, Ou J, Hutchinson L et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Molecular cell. 2014. [PMID 25219500](https://pubmed.ncbi.nlm.nih.gov/25219500/). DOI: 10.1016/j.molcel.2014.08.010. Access: abstract_metadata. Study: Green-MAFG-pathway.

44. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nature genetics. 2004. [PMID 15064764](https://pubmed.ncbi.nlm.nih.gov/15064764/). DOI: 10.1038/ng1342. Access: abstract_metadata. Study: PMID15064764.

45. Dámaso E, Castillejo A, Arias MDM et al. Primary constitutional MLH1 epimutations: a focal epigenetic event. British journal of cancer. 2018. [PMID 30283143](https://pubmed.ncbi.nlm.nih.gov/30283143/). DOI: 10.1038/s41416-018-0019-8. Access: abstract_metadata. Study: PMID30283143.

46. Savio AJ, Bapat B. Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer. Epigenetics. 2017. [PMID 28304185](https://pubmed.ncbi.nlm.nih.gov/28304185/). DOI: 10.1080/15592294.2017.1305527. Access: abstract_metadata. Study: PMID28304185.

47. Teschendorff AE, Gao Y, Jones A et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nature communications. 2016. [PMID 26823093](https://pubmed.ncbi.nlm.nih.gov/26823093/). DOI: 10.1038/ncomms10478. Access: abstract_metadata. Study: PMID26823093.

48. Irie T, Yamada H, Takeuchi C et al. The methylation level of a single cancer risk marker gene reflects methylation burden in gastric mucosa. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2023. [PMID 37219707](https://pubmed.ncbi.nlm.nih.gov/37219707/). DOI: 10.1007/s10120-023-01399-w. Access: abstract_metadata. Study: PMID37219707.

49. Yang L, Chen X, Lee C et al. Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer. Journal of experimental & clinical cancer research : CR. 2023. [PMID 37143122](https://pubmed.ncbi.nlm.nih.gov/37143122/). DOI: 10.1186/s13046-023-02689-y. Access: full_text_partial. Study: Shen-p16-cis-lineage.

50. Maekita T, Nakazawa K, Mihara M et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. [PMID 16467114](https://pubmed.ncbi.nlm.nih.gov/16467114/). DOI: 10.1158/1078-0432.CCR-05-2096. Access: abstract_metadata. Study: PMID16467114.

51. Nakajima T, Maekita T, Oda I et al. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006. [PMID 17119066](https://pubmed.ncbi.nlm.nih.gov/17119066/). DOI: 10.1158/1055-9965.EPI-06-0436. Access: abstract_metadata. Study: PMID17119066.

52. Tanaka I, Ono S, Watanabe Y et al. Long-term changes in aberrant DNA methylation and gastritis after Helicobacter pylori eradication focused on metachronous gastric cancer. Helicobacter. 2022. [PMID 35939560](https://pubmed.ncbi.nlm.nih.gov/35939560/). DOI: 10.1111/hel.12915. Access: abstract_metadata. Study: PMID35939560.

53. Suzuki R, Yamamoto E, Nojima M et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. Journal of gastroenterology. 2014. [PMID 23942619](https://pubmed.ncbi.nlm.nih.gov/23942619/). DOI: 10.1007/s00535-013-0861-7. Access: abstract_metadata. Study: PMID23942619.

54. Shin CM, Kim N, Yoon H et al. Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms. Cancer research and treatment. 2022. [PMID 35038821](https://pubmed.ncbi.nlm.nih.gov/35038821/). DOI: 10.4143/crt.2021.997. Access: abstract_metadata. Study: PMID35038821.

55. Wijetunga NA, Ben-Dayan M, Tozour J et al. A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma. Oncotarget. 2016. [PMID 27557505](https://pubmed.ncbi.nlm.nih.gov/27557505/). DOI: 10.18632/oncotarget.11390. Access: abstract_metadata. Study: PMID27557505.

56. Ghosh J, Schultz BM, Chan J et al. Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer. Cancer prevention research (Philadelphia, Pa.). 2022. [PMID 36219239](https://pubmed.ncbi.nlm.nih.gov/36219239/). DOI: 10.1158/1940-6207.CAPR-22-0258. Access: abstract_metadata. Study: PMID36219239.

57. Yates J, Schaufelberger H, Steinacher R et al. DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps. Journal of the National Cancer Institute. 2024. [PMID 38273663](https://pubmed.ncbi.nlm.nih.gov/38273663/). DOI: 10.1093/jnci/djae016. Access: full_text_partial. Study: PMID38273663.

58. Belshaw NJ, Pal N, Tapp HS et al. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis. 2010. [PMID 20395289](https://pubmed.ncbi.nlm.nih.gov/20395289/). DOI: 10.1093/carcin/bgq077. Access: abstract_metadata. Study: PMID20395289.

59. Sambuudash O, Kim HS, Cho MY. Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer. Yonsei medical journal. 2017. [PMID 28540987](https://pubmed.ncbi.nlm.nih.gov/28540987/). DOI: 10.3349/ymj.2017.58.4.749. Access: full_text_partial. Study: PMID28540987.

60. Niwa T, Tsukamoto T, Toyoda T et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer research. 2010. [PMID 20124475](https://pubmed.ncbi.nlm.nih.gov/20124475/). DOI: 10.1158/0008-5472.CAN-09-2755. Access: abstract_metadata. Study: Ushijima-gerbil-inflammation-platform.

61. Shen L, Kondo Y, Rosner GL et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. Journal of the National Cancer Institute. 2005. [PMID 16174854](https://pubmed.ncbi.nlm.nih.gov/16174854/). DOI: 10.1093/jnci/dji275. Access: abstract_metadata. Study: PMID16174854.

62. Hur K, Niwa T, Toyoda T et al. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis. 2011. [PMID 20980348](https://pubmed.ncbi.nlm.nih.gov/20980348/). DOI: 10.1093/carcin/bgq219. Access: abstract_metadata. Study: Ushijima-gerbil-inflammation-platform.

63. Yamada H, Abe S, Charvat H et al. Precision risk stratification of primary gastric cancer after eradication of H. pylori by a DNA methylation marker: a multicentre prospective study. Gut. 2025. [PMID 40240063](https://pubmed.ncbi.nlm.nih.gov/40240063/). DOI: 10.1136/gutjnl-2025-335039. Access: full_text_partial. Study: PMID40240063.

## Source-specific evidence cards

### [1] DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia.

**Shows:** DDR, mutation burden and repair-promoter methylation distinguish metaplastic states.

**Does not show:** Cross-sectional DDR markers and methylation do not establish an independent initiating clone.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [2] Frequent involvement of chromatin remodeler alterations in gastric field cancerization.

**Shows:** SMARCA1/ACTL6B methylation occurs in noncancerous tissue; remodeler depletion promotes cancer-cell growth.

**Does not show:** Mutation and methylation coexist; cancer-cell depletion does not reproduce spontaneous epithelial initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [3] Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation.

**Shows:** IM has a distinctive methylome and NOS2 induction accelerates methylation.

**Does not show:** An IM signature and artificial NOS2 induction do not show methylation alone initiates cancer.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [4] Degree of methylation burden is determined by the exposure period to carcinogenic factors.

**Shows:** Methylation burden increases with exposure and partly persists after withdrawal.

**Does not show:** Persistence is not proof of autonomous cancer initiation; related gastric platform is grouped.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [5] DNA demethylation in normal colon tissue predicts predisposition to multiple cancers.

**Shows:** LINE-1 hypomethylation associates with multiple cancers and predicts metachronous neoplasms.

**Does not show:** This is hypomethylation, not the proposed promoter hypermethylation; observational prediction is not causation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [6] Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.

**Shows:** GPX3 promoter methylation rises through metaplasia, dysplasia and adenocarcinoma with reduced expression.

**Does not show:** Stage association cannot resolve temporal initiation or independent clonal growth.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [7] Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.

**Shows:** Genetic and epigenetic profiles identify distinct mutation-defined colitis cancer groups.

**Does not show:** Tumor profiling is not a prospective test of normal methylated clone initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [8] Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal Cancer.

**Shows:** A stable early-onset case inherited a constitutional epimutation from a mosaic asymptomatic mother without detected sequence alteration.

**Does not show:** Rare constitutional predisposition differs from acquired epithelial field expansion; genomic absence remains bounded by detection.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [9] DNA methyltransferase inhibition reduces inflammation-induced colon tumorigenesis.

**Shows:** DNMT inhibition reduces tumorigenesis and persistent inflammatory methylation; derived tumoroids differ in proliferation.

**Does not show:** Broad drug effects, inflammatory context and shared precursor model prevent isolated spontaneous methylation sufficiency.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [10] Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent.

**Shows:** Demethylating treatment reduces cancer incidence with lower epithelial methylation.

**Does not show:** Inflammatory cytokines also change and carcinogen exposure remains; no locus-specific mediation rescue or spontaneous field test.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [11] Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study.

**Shows:** Preselected mucosal miR-124a-3 methylation predicts authentic later cancers with adjusted HR 2.30 and explicit early-event exclusion.

**Does not show:** Three-year follow-up, modest events and residual confounding limit causality; not all marker or endpoint analyses are significant.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Patients and methods, 2:Results. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [12] Severe induction of aberrant DNA methylation by nodular gastritis in adults.

**Shows:** Normal antral tissue in nodular gastritis has higher tumor-suppressor methylation, including in patients without cancer.

**Does not show:** Small cross-sectional groups and tissue-state effects do not isolate inflammatory causation or initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [13] Mismatch Repair Proteins Initiate Epigenetic Alterations during Inflammation-Driven Tumorigenesis.

**Shows:** MSH2 loss prevents early inflammation-associated epigenetic alterations and later hypermethylation.

**Does not show:** MSH2 also affects repair and tumor biology; linked erratum body remains unexamined, limiting fine mechanistic certainty.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID29339372. Subclaims: SC3.

### [14] Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis.

**Shows:** Gastritis activity correlates with promoter gains and repeat losses of methylation.

**Does not show:** Serological covariation is not an intervention or independent epimutation initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [15] Antibiotics suppress colon tumorigenesis through inhibition of aberrant DNA methylation in an azoxymethane and dextran sulfate sodium colitis model.

**Shows:** Antibiotics reduce inflammation, methylation markers and colon tumor burden together.

**Does not show:** Multiple pathways change; methylation mediation is not isolated and the model is not spontaneous.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [16] Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication.

**Shows:** Successful eradication reduces marker methylation with marker-specific kinetics but leaves residual levels above uninfected controls.

**Does not show:** Nonrandom intervention and cell-composition changes limit mediation; residual risk does not establish autonomous methylated clones.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [17] The landscape of somatic mutation in normal colorectal epithelial cells.

**Shows:** Probable drivers occur in about 1% of middle-age crypts; normal clonal evolution is genetically measurable.

**Does not show:** Driver presence is not sufficient for cancer and epigenomes were not jointly measured; mutation-first is not universally proved.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [18] Somatic Evolution in Non-neoplastic IBD-Affected Colon.

**Shows:** IBD increases mutations and millimetre-scale clonal expansion with tissue-specific positive selection.

**Does not show:** Control crypts reuse prior normal-colon publication; genetic selection does not exclude cooperative epigenetic effects.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [19] Somatic mutant clones colonize the human esophagus with age.

**Shows:** Normal epithelium becomes colonized by positively selected mutant clones, with NOTCH1 more prevalent than in cancers.

**Does not show:** Cross-sectional clonal genetics does not show every clone is malignant or resolve methylation's additional contribution.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [20] Tobacco smoking and somatic mutations in human bronchial epithelium.

**Shows:** Smoking increases mutational burden and driver prevalence; cessation associates with less-mutated cells.

**Does not show:** Colony culture and cross-sectional sampling constrain selection inference; no joint methylome lineage test.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [21] The somatic mutation landscape of normal gastric epithelium.

**Shows:** Distinct drivers and trisomies occur in normal glands; clone prevalence depends on age and inflammation, with normal/cancer CTNNB1 spectra differing.

**Does not show:** Normal clones are not equivalent to cancer and methylation is not jointly perturbed; cancer-bearing donors contribute samples.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 4:Driver mutations in gastric glands. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [22] Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

**Shows:** Positive selection produces abundant cancer-gene mutant clones while tissue remains functional.

**Does not show:** Four donors and targeted genes constrain coverage; genetic clone existence does not exclude epigenetic cooperation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [23] Stochastic epigenetic outliers can define field defects in cancer.

**Shows:** Outlier-sensitive statistical approaches detect reproducible premalignant methylation field patterns.

**Does not show:** Reused cohorts and algorithm comparisons are not independent causal interventions; biological selection is inferred.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [24] Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer.

**Shows:** A widespread histologically normal prostate field profile validates beyond immediate tumor proximity.

**Does not show:** Most altered loci are hypomethylated; cross-sectional tissue cannot establish initiation direction.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [25] Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa.

**Shows:** Age- and disease-associated CGI patterns discriminate normal mucosal groups.

**Does not show:** Classifier accuracy within sampled groups does not demonstrate prospective risk or independent initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [26] Quantitative, spatial resolution of the epigenetic field effect in prostate cancer.

**Shows:** Field methylation is gene- and case-specific; GSTP1 field change is absent while some loci extend beyond tumor.

**Does not show:** Small spatial sampling and occult-cell effects remain; lack of one marker is not absence of all fields.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [27] Promoter hypermethylation of resected bronchial margins: a field defect of changes?

**Shows:** Histologically negative margins often share tumor methylation but no significant recurrence correlation is found.

**Does not show:** Twenty patients and few recurrences limit power; negative margins do not prove independent normal clones.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [28] Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans.

**Shows:** MGMT/ADAMTS14 normal-mucosal fields correlate with age, but MGMT methylation has no significant KRAS/TP53 or exome G-to-A association.

**Does not show:** Null mutation association does not rule out other methylation consequences; cross-sectional ancestry associations are not causal mechanisms.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [29] Epigenetic inactivation of FAT4 contributes to gastric field cancerization.

**Shows:** FAT4 methylation silences expression and is associated with infection and cancer in noncancerous mucosa.

**Does not show:** Broad demethylation restores expression without demonstrating native field initiation or incidence.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [30] Methylated eyes absent 4 (EYA4) gene promotor in non-neoplastic mucosa of ulcerative colitis patients with colorectal cancer: evidence for a field effect.

**Shows:** EYA4 methylation is elevated beyond the tumor in UC cases with synchronous CRC.

**Does not show:** Synchronous case-control signal, wide odds-ratio uncertainty and incomplete tissue availability limit prospective inference.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [31] Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.

**Shows:** MGMT-deficient mucosal patches associate more often with MSI cancers.

**Does not show:** The proposed ordering from MGMT loss to MMR deficiency is inferred, not traced prospectively or selectively rescued.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [32] Enrichment of CpG island shore region hypermethylation in epigenetic breast field cancerization.

**Shows:** Ipsilateral normal breast shows CGI-shore changes relative to contralateral epithelium.

**Does not show:** Nine cancer-bearing women; contralateral tissue is not a cancer-free population and spatial ordering is not temporal causality.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [33] LINE-1 hypomethylation is neither present in rectal aberrant crypt foci nor associated with field defect in sporadic colorectal neoplasia.

**Shows:** LINE-1 field hypomethylation is absent; segment-specific methylation differences are detected.

**Does not show:** This negative result addresses repeat methylation, not every promoter field; rectal ACF differ from right-colon adenomas.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [34] Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect.

**Shows:** miR-34b/c methylation tracks multiple gastric cancer and restoration suppresses cancer-cell growth.

**Does not show:** Synthetic RNA restoration in cancer cells does not isolate spontaneous field initiation in vivo.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [35] Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication.

**Shows:** New correlated mucosal methylation markers discriminate gastric cancer from atrophic controls.

**Does not show:** Case-control discrimination is not prospective incidence; shared exposure and marker covariance remain.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [36] Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues.

**Shows:** Relative predictive contribution of genetic and epigenetic alterations differs by tissue.

**Does not show:** Risk groups are defined partly by existing cancer; targeted mutation assays do not establish epigenetic independence.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [37] Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary.

**Shows:** p16 silencing associates with CTCF boundary loss and altered protein regulation.

**Does not show:** Established cancer cells and correlated chromatin changes do not identify spontaneous normal epithelial field initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [38] TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts.

**Shows:** Locus-directed suppression increases replication and p16 restoration reverses the phenotype.

**Does not show:** Fibroblast replication is not epithelial malignancy or spontaneous in-vivo incidence; engineered delivery defines scope.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [39] Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice.

**Shows:** Engineered promoter methylation represses p16 and raises spontaneous tumor incidence without a required engineered oncogene; inserted-sequence controls and expression restoration support mechanism.

**Does not show:** The initiating allele is engineered DNA; mixed backgrounds, small tumor cohorts, non-epithelial tumor spectrum and absent whole-genome lineage/rescue constrain natural-field transfer.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Publisher HTML paragraphs:paragraph39, 0:Publisher HTML paragraphs:paragraph40, 0:Publisher HTML paragraphs:paragraph42, 0:Publisher HTML paragraphs:paragraph44, 0:Publisher HTML paragraphs:paragraph45, 0:Publisher HTML paragraphs:paragraph46. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [40] A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.

**Shows:** KRAS-linked ZNF304 recruitment mediates DNMT1-associated CIMP silencing.

**Does not show:** Cancer-cell dependency is not universal mutation-first initiation; related RNAi platform is grouped.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [41] Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.

**Shows:** BRAF-MAFG corepressor pathway directs methylation-linked silencing in two cancer settings.

**Does not show:** Shares pathway/platform with earlier CRC report; no proof that all natural methylation fields originate genetically.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [42] Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis.

**Shows:** Spontaneous culture-associated methylation creates Wnt/stemness changes and sharply accelerates Braf-dependent transformation.

**Does not show:** Culture aging is not chronological native epithelium; Braf is required in the tested transformation comparison and some selected outgrowths acquire Wnt mutations.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph8, 1:RESULTS:paragraph11, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13, 1:RESULTS:paragraph14, 1:RESULTS:paragraph15, 1:RESULTS:paragraph16, 1:RESULTS:paragraph17. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [43] The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.

**Shows:** MAFG depletion resolves an oncogene-directed MLH1/CIMP repression pathway.

**Does not show:** Related study line and established tumor cells limit initiation transfer; does not erase epigenetic-first sensitization.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [44] Germline epimutation of MLH1 in individuals with multiple cancers.

**Shows:** Soma-wide allele-specific MLH1 methylation accompanies multiple mismatch-repair-deficient tumors without detected MMR mutation.

**Does not show:** Rare constitutional predisposition and bounded mutation detection do not establish common acquired epithelial field expansion.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [45] Primary constitutional MLH1 epimutations: a focal epigenetic event.

**Shows:** Ten carriers lack detected cis nucleotide/structural variants; the focal methylation event can erase across generations.

**Does not show:** Other CNVs in two cases and unsolved mechanism constrain pure epigenetic independence; rare constitutional scope remains.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [46] Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer.

**Shows:** MLH1 promoter genotype alters AP4 binding and shore methylation.

**Does not show:** Local genetic regulation need not explain all MLH1 epimutations or spontaneous field clones.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

### [47] DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer.

**Shows:** Outlier fields enrich architecture-factor loci and progress in paired cancer samples.

**Does not show:** Computational cellular-mixture adjustment and cross-sectional tissue cannot establish clonal causality; related outlier algorithms share assumptions.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [48] The methylation level of a single cancer risk marker gene reflects methylation burden in gastric mucosa.

**Shows:** Single-marker methylation correlates with genome-wide burden and candidate driver methylation.

**Does not show:** Biomarker covariance is not mediation or independent initiation; discovery and validation sample roles differ.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [49] Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer.

**Shows:** p16 epimutation cooperates with Apc, changes immune milieu and tumor progression; targeted demethylation restores p16 in fibroblasts.

**Does not show:** Shared cis-element lineage with Yu; tumors arise in Apc-mutant context and broad drug/immune effects prevent autonomous initiation inference.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph5, 2:Results:paragraph17. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

### [50] High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk.

**Shows:** Methylation is strongly associated with infection and, after exposure stratification, with existing cancer.

**Does not show:** Cross-sectional exposure signal and variability are not independent epigenetic initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [51] Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers.

**Shows:** Post-infection marker methylation increases across cancer-risk groups after atrophy adjustment.

**Does not show:** Existing multiple cancers define risk groups; association does not trace or perturb a field clone.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [52] Long-term changes in aberrant DNA methylation and gastritis after Helicobacter pylori eradication focused on metachronous gastric cancer.

**Shows:** Marker methylation improves after eradication in some groups but persists with metachronous cancer.

**Does not show:** Outcome-selected groups and limited sample sizes are not a preregistered independent causal test.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

### [53] Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk.

**Shows:** Baseline miR-34b/c predicts later cancer after covariate adjustment in 129 patients.

**Does not show:** Seventeen events and observational tissue markers do not establish independent methylation-driven initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [54] Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms.

**Shows:** Baseline MOS predicts later metachronous neoplasms with adjusted HR 4.76.

**Does not show:** Only 124 of 294 completed the protocol; outcome mixes adenomas and seven cancers and threshold requires external validation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

### [55] A polycomb-mediated epigenetic field defect precedes invasive cervical carcinoma.

**Shows:** Early polycomb-target methylation and local expression changes persist through progression.

**Does not show:** Stage ordering is not prospective clonal tracing; HPV context precludes autonomous epigenetic initiation inference.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [56] Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer.

**Shows:** Outlier methylation phenotype occurs in 15/77 CRC cases versus 0/68 controls with transcriptional changes.

**Does not show:** Case-control OMP signal is not prospective incidence or proof of microbial or methylation causal ordering.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [57] DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.

**Shows:** 558 loci distinguish adenoma-adjacent mucosa, with external validation and age/cell-composition checks.

**Does not show:** AUC is cross-sectional classification, not prediction of subsequent incident cancer; many loci associate with age.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph10, 1:Results:paragraph14, 1:Results:paragraph15. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [58] Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa.

**Shows:** Crypt methylation varies within donors and associates with age/disease, with all-or-none CGI patterns.

**Does not show:** Clonal units are sampled cross-sectionally without genome/epigenome fate tracking; combined mutation mechanism is proposed.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [59] Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer.

**Shows:** Most candidate methylation fields are absent despite strong tumor signals; adjacent hotspots are negative.

**Does not show:** Candidate panel and modest cohort cannot exclude every epimutation; abstract/body single-locus estimates differ and are not pooled.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 2:RESULTS. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [60] Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells.

**Shows:** Suppressing inflammation leaves bacterial colonization intact but blocks methylation induction; withdrawal leaves a residual component.

**Does not show:** Broad immunosuppression and exposure-defined tissue do not isolate autonomous methylation-mediated cancer initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [61] MGMT promoter methylation and field defect in sporadic colorectal cancer.

**Shows:** Multiple assays detect MGMT fields well beyond tumors and associate tumor methylation with KRAS transitions.

**Does not show:** Normal-mucosal mutation association is nonsignificant; ordering and clonal fitness are not directly tested.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

### [62] Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation.

**Shows:** Strong proliferation alone fails to induce the same methylation; inflammatory type matters.

**Does not show:** Related gastric platform and different exposures limit independent replication; outcome is methylation rather than cancer incidence.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [63] Precision risk stratification of primary gastric cancer after eradication of H. pylori by a DNA methylation marker: a multicentre prospective study.

**Shows:** 1624 followed participants with 27 incident cancers validate RIMS1 risk gradients with adjusted HR 5.7.

**Does not show:** Wide interval and atrophy-selected population constrain transfer; marker burden validation uses separate archived samples, and methylation is not experimentally altered.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Results. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.